» Articles » PMID: 37175698

NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease of very high prevalence, especially in childhood, with no specific treatment or cure. As its pathogenesis is complex, multifactorial and not fully understood, further research is needed to increase knowledge and develop new targeted therapies. We have recently demonstrated the critical role of NAD and poly (ADP-ribose) (PAR) metabolism in oxidative stress and skin inflammation. Specifically, we found that hyperactivation of PARP1 in response to DNA damage induced by reactive oxygen species, and fueled by NAMPT-derived NAD, mediated inflammation through parthanatos cell death in zebrafish and human organotypic 3D skin models of psoriasis. Furthermore, the aberrant induction of NAMPT and PARP activity was observed in the lesional skin of psoriasis patients, supporting the role of these signaling pathways in psoriasis and pointing to NAMPT and PARP1 as potential novel therapeutic targets in treating skin inflammatory disorders. In the present work, we report, for the first time, altered NAD and PAR metabolism in the skin of AD patients and a strong correlation between NAMPT and PARP1 expression and the lesional status of AD. Furthermore, using a human 3D organotypic skin model of AD, we demonstrate that the pharmacological inhibition of NAMPT and PARP reduces pathology-associated biomarkers. These results help to understand the complexity of AD and reveal new potential treatments for AD patients.

Citing Articles

Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis.

Monedeiro F, Ehall B, Tiffner K, Eberl A, Svehlikova E, Prietl B J Proteome Res. 2024; 23(8):3496-3514.

PMID: 38986055 PMC: 11304394. DOI: 10.1021/acs.jproteome.4c00153.


The potential of zebrafish as drug discovery research tool in immune-mediated inflammatory disease.

Smith C Inflammopharmacology. 2024; 32(4):2219-2233.

PMID: 38926297 PMC: 11300644. DOI: 10.1007/s10787-024-01511-1.


Special Issue "Molecular and Cellular Advances in Atopic Diseases".

Cabanillas B Int J Mol Sci. 2024; 25(9).

PMID: 38732073 PMC: 11084155. DOI: 10.3390/ijms25094856.


PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages.

Santinelli-Pestana D, Aikawa E, Singh S, Aikawa M Pathogens. 2023; 12(7).

PMID: 37513811 PMC: 10386340. DOI: 10.3390/pathogens12070964.

References
1.
Ismail S, Mohamed S . Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol. 2012; 167(2):436-9. DOI: 10.1111/j.1365-2133.2012.10980.x. View

2.
Kanda N, Hau C, Tada Y, Tatsuta A, Sato S, Watanabe S . Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology. 2011; 152(8):3155-64. DOI: 10.1210/en.2010-1481. View

3.
Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Morimura S, Kai H . Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma. Eur J Dermatol. 2013; 23(5):629-35. DOI: 10.1684/ejd.2013.2107. View

4.
Mobus L, Rodriguez E, Harder I, Stolzl D, Boraczynski N, Gerdes S . Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol. 2020; 147(1):213-223. DOI: 10.1016/j.jaci.2020.06.012. View

5.
Wollenberg A, Szepietowski J, Taieb A, Ring J . Corrigendum: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2019; 33(7):1436. DOI: 10.1111/jdv.15719. View